MTOR and cancer: To the bestof our knowledge, this study was the first to demonstrate the feasibilityto codeliver a Pt-based chemotherapeutic agent and a PI3K/mTOR dualinhibitor into cancer cells without introducing any foreign materials.Our approach represents a safe and effective platform to tackle theexisting hindrance in the combination therapy of CDDP and PI3K/mTORdual inhibitors in the hope of achieving further industrial and clinicalapplication for enhanced therapeutic outcomes in treating solid tumors.